Use of Tumor-Infiltrating Lymphocytes and Interleukin-2 in the Immunotherapy of Patients with Metastatic Melanoma, New England Journal of Medicine, vol.319, issue.25, pp.1676-80, 1988. ,
DOI : 10.1056/NEJM198812223192527
Restoration of viral immunity in immunodeficient humans by the adoptive transfer of T cell clones, Science, vol.257, issue.5067, pp.238-279, 1992. ,
DOI : 10.1126/science.1352912
Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr-virus-related lymphoproliferation, The Lancet, vol.345, issue.8941, pp.9-13, 1995. ,
DOI : 10.1016/S0140-6736(95)91150-2
Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen, Blood, vol.114, issue.3, pp.535-581, 2009. ,
DOI : 10.1182/blood-2009-03-211714
URL : http://www.bloodjournal.org/content/bloodjournal/114/3/535.full.pdf
T Cells Targeting Carcinoembryonic Antigen Can Mediate Regression of Metastatic Colorectal Cancer but Induce Severe Transient Colitis, Molecular Therapy, vol.19, issue.3, pp.620-626, 2011. ,
DOI : 10.1038/mt.2010.272
URL : https://doi.org/10.1038/mt.2010.272
Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells, Nature Medicine, vol.360, issue.6, pp.747-52, 2013. ,
DOI : 10.1038/360171a0
URL : http://europepmc.org/articles/pmc3757932?pdf=render
Targeting cancer-specific mutations by T cell receptor gene therapy, Current Opinion in Immunology, vol.33, pp.112-121, 2015. ,
DOI : 10.1016/j.coi.2015.02.005
URL : http://europepmc.org/articles/pmc4557613?pdf=render
Cancer Regression in Patients After Transfer of Genetically Engineered Lymphocytes, Science, vol.314, issue.5796, pp.126-135, 2006. ,
DOI : 10.1126/science.1129003
NY-ESO-1???specific TCR???engineered T cells mediate sustained antigen-specific antitumor effects in myeloma, Nature Medicine, vol.72, issue.8, pp.914-935, 2015. ,
DOI : 10.1182/blood-2009-04-217604
URL : http://europepmc.org/articles/pmc4529359?pdf=render
Tumor Regression in Patients With Metastatic Synovial Cell Sarcoma and Melanoma Using Genetically Engineered Lymphocytes Reactive With NY-ESO-1, Journal of Clinical Oncology, vol.29, issue.7, pp.917-941, 2011. ,
DOI : 10.1200/JCO.2010.32.2537
URL : http://europepmc.org/articles/pmc3068063?pdf=render
Functional Comparison of Engineered T Cells Carrying a Native TCR versus TCR-like Antibody???Based Chimeric Antigen Receptors Indicates Affinity/Avidity Thresholds, The Journal of Immunology, vol.193, issue.11, pp.5733-5776, 2014. ,
DOI : 10.4049/jimmunol.1301769
URL : http://www.jimmunol.org/content/jimmunol/193/11/5733.full.pdf
Peptide-specific killing of antigen-presenting cells by a recombinant antibody-toxin fusion protein targeted to major histocompatibility complex/peptide class I complexes with T cell receptor-like specificity, Proceedings of the National Academy of Sciences, vol.1, issue.8, pp.4631-4637, 1997. ,
DOI : 10.1038/nm0895-837
Optimized T-cell receptor-mimic chimeric antigen receptor T cells directed toward the intracellular Wilms Tumor 1 antigen, Leukemia, vol.5, issue.8, 2017. ,
DOI : 10.1126/scitranslmed.3004916
URL : http://europepmc.org/articles/pmc5495623?pdf=render
Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors., Proceedings of the National Academy of Sciences, vol.90, issue.2, pp.720-724, 1993. ,
DOI : 10.1073/pnas.90.2.720
Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity., Proceedings of the National Academy of Sciences, vol.86, issue.24, pp.10024-10032, 1989. ,
DOI : 10.1073/pnas.86.24.10024
URL : http://www.pnas.org/content/86/24/10024.full.pdf
A Phase I Study on Adoptive Immunotherapy Using Gene-Modified T Cells for Ovarian Cancer, Clinical Cancer Research, vol.12, issue.20, pp.6106-6121, 2006. ,
DOI : 10.1158/1078-0432.CCR-06-1183
URL : http://clincancerres.aacrjournals.org/content/clincanres/12/20/6106.full.pdf
Process validation and clinical evaluation of a protocol to generate gene-modified T lymphocytes for imunogene therapy for metastatic renal cell carcinoma: GMP-controlled transduction and expansion of patient's T lymphocytes using a carboxy anhydrase IX-specific scFv transgene, Cytotherapy, vol.8, issue.6, pp.542-53, 2006. ,
DOI : 10.1080/14653240601056396
Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells, Blood, vol.112, issue.6, pp.2261-71, 2008. ,
DOI : 10.1182/blood-2007-12-128843
URL : http://www.bloodjournal.org/content/bloodjournal/112/6/2261.full.pdf
CD20-specific adoptive immunotherapy for lymphoma using a chimeric antigen receptor with both CD28 and 4-1BB domains: pilot clinical trial results, Blood, vol.119, issue.17, pp.3940-50, 2012. ,
DOI : 10.1182/blood-2011-10-387969
URL : http://www.bloodjournal.org/content/bloodjournal/119/17/3940.full.pdf
Increasing the safety and efficacy of chimeric antigen receptor T cell therapy, Protein & Cell, vol.6, issue.10, pp.13238-13255, 2017. ,
DOI : 10.18632/oncotarget.2767
URL : https://link.springer.com/content/pdf/10.1007%2Fs13238-017-0411-9.pdf
The Principles of Engineering Immune Cells to Treat Cancer, Cell, vol.168, issue.4, pp.724-764, 2017. ,
DOI : 10.1016/j.cell.2017.01.016
URL : http://europepmc.org/articles/pmc5553442
Chimeric Antigen Receptor T Cells and Hematopoietic Cell Transplantation: How Not to Put the CART Before the Horse, Biology of Blood and Marrow Transplantation, vol.23, issue.2, pp.235-281, 2017. ,
DOI : 10.1016/j.bbmt.2016.09.002
URL : http://europepmc.org/articles/pmc5237606?pdf=render
CD19-Targeted CAR T cells as novel cancer immunotherapy for relapsed or refractory B-cell acute lymphoblastic leukemia, Clin Adv Hematol Oncol, vol.14, pp.802-810, 2016. ,
CD19 Antigen in Leukemia and Lymphoma Diagnosis and Immunotherapy, Leukemia & Lymphoma, vol.50, issue.5-6, pp.385-97, 1995. ,
DOI : 10.1016/0145-2126(87)90166-4
Abnormal B lymphocyte delevopment, activation, and differentiation in mice that lack or overexpress the CD19 signal transduction molecule, Immunity, vol.3, issue.1, pp.39-50, 1995. ,
DOI : 10.1016/1074-7613(95)90157-4
URL : https://doi.org/10.1016/1074-7613(95)90157-4
Gene, New England Journal of Medicine, vol.354, issue.18, pp.1901-1913, 2006. ,
DOI : 10.1056/NEJMoa051568
Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19, Blood, vol.116, issue.20, pp.4099-102, 2010. ,
DOI : 10.1182/blood-2010-04-281931
A transgene-encoded cell surface polypeptide for selection, in vivo tracking, and ablation of engineered cells, Blood, vol.118, issue.5, pp.1255-63, 2011. ,
DOI : 10.1182/blood-2011-02-337360
A highly compact epitope-based marker/suicide gene for easier and safer T-cell therapy, Blood, vol.124, issue.8, pp.1277-87, 2014. ,
DOI : 10.1182/blood-2014-01-545020
URL : http://www.bloodjournal.org/content/bloodjournal/124/8/1277.full.pdf
Remote control of therapeutic T cells through a small molecule-gated chimeric receptor, Science, vol.14, issue.6, p.4077, 2015. ,
DOI : 10.1016/j.sbi.2004.10.004
URL : http://europepmc.org/articles/pmc4721629?pdf=render
Dual Targeting of ErbB2 and MUC1 in Breast Cancer Using Chimeric Antigen Receptors Engineered to Provide Complementary Signaling, Journal of Clinical Immunology, vol.19, issue.5, pp.1059-70, 2012. ,
DOI : 10.1038/mt.2011.9
Combinatorial antigen recognition with balanced signaling promotes selective tumor eradication by engineered T cells, Nature Biotechnology, vol.3, issue.1, pp.71-76, 2013. ,
DOI : 10.1073/pnas.86.10.3833
URL : http://europepmc.org/articles/pmc5505184?pdf=render
CAR T Cell Therapy for Solid Tumors, Annual Review of Medicine, vol.68, issue.1, pp.139-52, 2017. ,
DOI : 10.1146/annurev-med-062315-120245
Current approaches to increase CAR T cell potency in solid tumors: targeting the tumor microenvironment, Journal for ImmunoTherapy of Cancer, vol.375, issue.1, p.28, 2017. ,
DOI : 10.1056/NEJMoa1610497
A Chimeric Switch-Receptor Targeting PD1 Augments the Efficacy of Second-Generation CAR T Cells in Advanced Solid Tumors, Cancer Research, vol.76, issue.6, pp.1578-90, 2016. ,
DOI : 10.1158/0008-5472.CAN-15-2524
Repeated loss of target surface antigen after immunotherapy in primary mediastinal large B cell lymphoma, American Journal of Hematology, vol.7, issue.1, pp.11-14, 2017. ,
DOI : 10.1038/ncomms12320
URL : http://onlinelibrary.wiley.com/doi/10.1002/ajh.24594/pdf
Chimeric antigen receptor T cell therapy: 25years in the making, Blood Reviews, vol.30, issue.3, pp.157-67, 2016. ,
DOI : 10.1016/j.blre.2015.10.003
The Evolution of T-cell Therapies for Solid Malignancies, Clinical Cancer Research, vol.21, issue.15, pp.3384-92, 2015. ,
DOI : 10.1158/1078-0432.CCR-14-2675
Case Report of a Serious Adverse Event Following the Administration of T Cells Transduced With a Chimeric Antigen Receptor Recognizing ERBB2, Molecular Therapy, vol.18, issue.4, pp.843-51, 2010. ,
DOI : 10.1038/mt.2010.24
Treatment of Metastatic Renal Cell Carcinoma With CAIX CAR-engineered T cells: Clinical Evaluation and Management of On-target Toxicity, Molecular Therapy, vol.21, issue.4, pp.904-916, 2013. ,
DOI : 10.1038/mt.2013.17
Precision Tumor Recognition by T Cells With Combinatorial Antigen-Sensing Circuits, Cell, vol.164, issue.4, pp.770-779, 2016. ,
DOI : 10.1016/j.cell.2016.01.011
URL : https://doi.org/10.1016/j.cell.2016.01.011
Engineering T Cells with Customized Therapeutic Response Programs Using Synthetic Notch Receptors, Cell, vol.167, issue.2, pp.419-451, 2016. ,
DOI : 10.1016/j.cell.2016.09.011
URL : http://europepmc.org/articles/pmc5072533?pdf=render
Ganciclovir treatment of herpes simplex thymidine kinase-transduced primary T lymphocytes: an approach for specific in vivo donor T-cell depletion after bone marrow transplantation, Blood, vol.84, pp.1333-1374, 1994. ,
HSV-TK Gene Transfer into Donor Lymphocytes for Control of Allogeneic Graft-Versus-Leukemia, Science, vol.276, issue.5319, pp.1719-1743, 1997. ,
DOI : 10.1126/science.276.5319.1719
Engineering CD19-specific T lymphocytes with interleukin-15 and a suicide gene to enhance their anti-lymphoma/leukemia effects and safety, Leukemia, vol.175, issue.6, pp.1160-70, 2010. ,
DOI : 10.1016/j.bbmt.2007.04.005
URL : http://www.nature.com/leu/journal/v24/n6/pdf/leu201075a.pdf
Of CARs and TRUCKs: chimeric antigen receptor (CAR) T cells engineered with an inducible cytokine to modulate the tumor stroma, Immunological Reviews, vol.60, issue.1, pp.83-90, 2014. ,
DOI : 10.1007/s00262-011-0998-2
Tumor-targeted T cells modified to secrete IL-12 eradicate systemic tumors without need for prior conditioning, Blood, vol.119, issue.18, pp.4133-4174, 2012. ,
DOI : 10.1182/blood-2011-12-400044
URL : http://www.bloodjournal.org/content/bloodjournal/119/18/4133.full.pdf
Tumor-Infiltrating Lymphocytes Genetically Engineered with an Inducible Gene Encoding Interleukin-12 for the Immunotherapy of Metastatic Melanoma, Clinical Cancer Research, vol.21, issue.10 ,
DOI : 10.1158/1078-0432.CCR-14-2085
Engager T Cells: A New Class of Antigen-specific T Cells That Redirect Bystander T Cells, Molecular Therapy, vol.23, issue.1, pp.171-179, 2015. ,
DOI : 10.1038/mt.2014.156
URL : https://doi.org/10.1038/mt.2014.156
Inhibition of tumor growth in vivo by in situ secretion of bispecific anti-CEA ?? anti-CD3 diabodies from lentivirally transduced human lymphocytes, Cancer Gene Therapy, vol.9, issue.4, pp.380-388, 2007. ,
DOI : 10.1007/978-3-642-56114-6_2
Enhanced Tumor Trafficking of GD2 Chimeric Antigen Receptor T Cells by Expression of the Chemokine Receptor CCR2b, Journal of Immunotherapy, vol.33, issue.8, pp.780-788, 2010. ,
DOI : 10.1097/CJI.0b013e3181ee6675
Expression of a Functional CCR2 Receptor Enhances Tumor Localization and Tumor Eradication by Retargeted Human T cells Expressing a Mesothelin-Specific Chimeric Antibody Receptor, Clinical Cancer Research, vol.17, issue.14, pp.4719-4749, 2011. ,
DOI : 10.1158/1078-0432.CCR-11-0351
Targeting Fibroblast Activation Protein in Tumor Stroma with Chimeric Antigen Receptor T Cells Can Inhibit Tumor Growth and Augment Host Immunity without Severe Toxicity, Cancer Immunology Research, vol.2, issue.2, pp.154-66, 2014. ,
DOI : 10.1158/2326-6066.CIR-13-0027
URL : http://cancerimmunolres.aacrjournals.org/content/canimm/2/2/154.full.pdf
Heparanase promotes tumor infiltration and antitumor activity of CAR-redirected T lymphocytes, Nature Medicine, vol.17, issue.5, pp.524-533, 2015. ,
DOI : 10.1016/j.neo.2014.11.007
URL : http://europepmc.org/articles/pmc4425589?pdf=render
Augmentation of CAR T-cell Trafficking and Antitumor Efficacy by Blocking Protein Kinase A Localization, Cancer Immunology Research, vol.4, issue.6, pp.541-51, 2016. ,
DOI : 10.1158/2326-6066.CIR-15-0263
URL : http://cancerimmunolres.aacrjournals.org/content/canimm/4/6/541.full.pdf
Transforming Growth Factor-?? Receptor Blockade Augments the Effectiveness of Adoptive T-Cell Therapy of Established Solid Cancers, Clinical Cancer Research, vol.14, issue.12, pp.3966-74, 2008. ,
DOI : 10.1158/1078-0432.CCR-08-0356
Adapting a transforming growth factor beta -related tumor protection strategy to enhance antitumor immunity, Blood, vol.99, issue.9, pp.3179-87, 2002. ,
DOI : 10.1182/blood.V99.9.3179
URL : http://www.bloodjournal.org/content/bloodjournal/99/9/3179.full.pdf
Chimeric Antigen Receptor T Cells Shape Myeloid Cell Function within the Tumor Microenvironment through IFN-?? and GM-CSF, The Journal of Immunology, vol.188, issue.12, pp.6389-98, 2012. ,
DOI : 10.4049/jimmunol.1103019
URL : http://www.jimmunol.org/content/jimmunol/188/12/6389.full.pdf
IL-7 and IL-21 are superior to IL-2 and IL-15 in promoting human T cell-mediated rejection of systemic lymphoma in immunodeficient mice, Blood, vol.115, issue.17, pp.3508-3527, 2010. ,
DOI : 10.1182/blood-2009-09-241398
Blockade of Programmed Death 1 Augments the Ability of Human T Cells Engineered to Target NY-ESO-1 to Control Tumor Growth after Adoptive Transfer, Clinical Cancer Research, vol.22, issue.2, pp.436-483, 2016. ,
DOI : 10.1158/1078-0432.CCR-15-1070
Anti-PD-1 Antibody Therapy Potently Enhances the Eradication of Established Tumors By Gene-Modified T Cells, Clinical Cancer Research, vol.19, issue.20, pp.5636-5682, 2013. ,
DOI : 10.1158/1078-0432.CCR-13-0458
URL : http://clincancerres.aacrjournals.org/content/clincanres/19/20/5636.full.pdf
Impact of a New Fusion Receptor on PD-1???Mediated Immunosuppression in Adoptive T Cell Therapy, JNCI: Journal of the National Cancer Institute, vol.20, issue.9, 2015. ,
DOI : 10.1158/1078-0432.CCR-13-3017
Enhanced Effector Responses in Activated CD8+ T Cells Deficient in Diacylglycerol Kinases, Cancer Research, vol.73, issue.12, pp.3566-77, 2013. ,
DOI : 10.1158/0008-5472.CAN-12-3874
URL : http://cancerres.aacrjournals.org/content/canres/73/12/3566.full.pdf